(Q34398524)

1 August 2017

title

Medicine. How thalidomide works against cancer (English)

1 reference

1 August 2017

0 references

A Keith Stewart

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

1 August 2017

number of pages

2

1 reference

based on heuristic

inferred from page(s)

published in

Science

1 reference

1 August 2017

volume

343

1 reference

1 August 2017

issue

6168

1 reference

1 August 2017

page(s)

256-257

1 reference

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

The clinical significance of cereblon expression in multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

IMWG consensus on maintenance therapy in multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Identification of a primary target of thalidomide teratogenicity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

IRF4 addiction in multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Antitumor activity of thalidomide in refractory multiple myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

The Ikaros gene is required for the development of all lymphoid lineages

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4084783

How I treat multiple myeloma in younger patients

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1126%2FSCIENCE.1249543

Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1126%2FSCIENCE.1249543

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1126%2FSCIENCE.1249543

21 January 2018

Identifiers

DOI

10.1126/SCIENCE.1249543

1 reference

1 August 2017

1 reference

1 August 2017

1 reference